Certinal eSign, a leader in Digital Transaction Management, has strengthened its strategic partnership with Bumrungrad International Hospital, a globally recognized healthcare provider, to revolutionize patient registration and data management. This expanded collaboration will drive greater efficiencies, improve security, and transform…
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing innovative treatments for severe ischemic diseases, today announced that the first patient has been dosed in its investigator-sponsored Phase 2 trial of DM199 for preeclampsia (PE). The company…
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company focused on using patients’ own biology to treat rare diseases, presented safety data from its Phase 3 ATTeST (Ataxia-Telangiectasia Trial with the EryDex SysTem) clinical trial at the 53rd Child Neurology…
Geron Corporation (Nasdaq: GERN), a biopharmaceutical leader focused on transforming the treatment of blood cancers, announced today the appointment of Joseph Eid, M.D., as Executive Vice President of Research and Development (R&D), effective November 11, 2024. In his new role,…
LivaNova PLC (Nasdaq: LIVN), a leading medical technology company, today announced that its OSPREY randomized controlled trial (RCT) met its primary safety and efficacy endpoints. The trial, which evaluated the LivaNova aura6000™ System for treating obstructive sleep apnea (OSA) using…
Hero Digital, a leading digital customer experience agency, has won several prestigious eHealthcare Leadership Awards for its outstanding work with UNC Health and Atlantic Health System. These awards recognize the most exceptional healthcare websites and digital initiatives, underscoring the crucial…
Neurogene Inc. (Nasdaq: NGNE), a clinical-stage biotechnology company focused on developing genetic medicines for rare neurological diseases, today reported positive interim results from the first four participants in the low-dose cohort of its ongoing Phase 1/2 open-label clinical trial evaluating…
TriSalus Life Sciences® Inc. (Nasdaq: TLSI), an oncology-focused company committed to improving outcomes for liver cancer patients through its advanced drug delivery technology and investigational immunotherapy nelitolimod, has entered into a strategic partnership with Geo-Med, LLC, a certified Service-Disabled Veteran-Owned…
Cyrus Biotechnology, Inc., a Seattle-based biotech company leveraging a novel hybrid AI/screening platform for biologics discovery, will showcase its expertise in protein engineering and risk mitigation for therapeutics at the inaugural Hit ID Summit in Boston. The presentation, scheduled for…
Care Access, a global leader in clinical research dedicated to advancing the future of medicine, is bringing its Heart & Kidney Health Screening initiative to Glendale, Arizona. The program aims to raise awareness and offer testing for key health risk…
Almirall, S.A. (ALM), a global biopharmaceutical company based in Barcelona, today reported its financial results for the first nine months of 2024. The company posted strong sales growth, primarily driven by its dermatology business, particularly the biologics portfolio in Europe.…
Oncoinvent ASA, a clinical-stage company developing alpha emitter therapies for solid cancers, today reported interim data from the Phase 1/2a trials of Radspherin® for the treatment of peritoneal carcinomatosis. Recruitment for these studies concluded at the end of 2023, with…